Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple test predict stomach cancer return?

NCT ID NCT04665687

Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is collecting tissue and blood samples from 1,730 people with early gastric cancer or precancerous stomach growths. Researchers will analyze the genetic profiles of these samples to find markers that could help diagnose these conditions early and predict if the cancer might come back after treatment. The goal is to improve personalized care for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to diagnose early gastric cancer and predict which patients might have a recurrence after treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and the markers identified may not prove useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,730 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 1730 patients with early gastric cancer and precancerous gastric adenoma will be enrolled. Based on previous studies, approximately 20% of the subjects are expected to have mutations. In this study, metachronous tumor recurrence rate between the mutation group and non-mutation group will be compared. In general, metachronous tumor recurrent rate after endoscopic resection for early gastric cancer or gastric ademona is reported to be 6%-10%. In this study, the metachronous tumor recurrence rate is expected to be 10% and 5% in the mutation and non-mutation group, respectively. When a two-sided chi-square test with a power of 5% and 90% type 1 error is performed, 346 and 1384 subjected are expected to be included in the mutation group and non-mutation group, respectively.

Ages

19 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Those who are over the age of 19 2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma 3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis 4. Those whose life expectancy is more than 3 months 5. Those who have voluntarily consented to participate in this clinical trial Exclusion Criteria: 1. Those who will not yield enough samples 2. Those who are considered inappropriate for this study in the discretion of the researchers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenoma gastric neoplasm microinvasive gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early gastric cancer Gastric adenoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung medical center

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.